Subtopic Deep Dive
Targeted Therapy in Small Cell Lung Cancer
Research Guide
What is Targeted Therapy in Small Cell Lung Cancer?
Targeted therapy in small cell lung cancer (SCLC) develops PARP inhibitors for SLFN11-high tumors and Aurora kinase antagonists exploiting SCLC replication stress.
Proteomic studies identify PARP1 as a key target in SCLC due to dysregulated DNA damage response pathways (Byers et al., 2012, 555 citations). Clinical trials test PARP inhibitors like niraparib and veliparib combined with chemotherapy or immunotherapy in relapsed SCLC (Pietanza et al., 2018, 387 citations; Sen et al., 2019, 837 citations). Over 10 papers from 2006-2023 explore DDR targeting to enhance antitumor immunity via STING pathway activation.
Why It Matters
PARP inhibitors sensitize SCLC to chemotherapy by exploiting replication stress, improving outcomes in platinum-resistant cases (Byers et al., 2012). Combining PARP inhibition with PD-1 blockade activates STING-mediated T-cell responses, boosting immunotherapy efficacy in SCLC where single-agent ICB fails (Sen et al., 2019). Veliparib plus temozolomide shows promise in relapsed-sensitive SCLC, with phase II trials demonstrating progression-free survival benefits (Pietanza et al., 2018). DLL3-targeted approaches address rare actionable mutations post-chemotherapy failure (Sabari et al., 2017).
Key Research Challenges
Limited Actionable Targets
SCLC lacks common driver mutations unlike NSCLC, restricting targeted options to rare targets like DLL3 (Sabari et al., 2017). Proteomic profiling reveals PARP1 vulnerability but broad applicability remains low (Byers et al., 2012). Developing biomarkers for SLFN11-high subsets is essential for patient selection.
Drug Resistance in Relapse
Platinum-resistant SCLC shows poor response to PARP inhibitors alone, necessitating combinations like veliparib-temozolomide (Pietanza et al., 2018). DDR pathway adaptations drive resistance post-initial therapy (Sen et al., 2019). Overcoming replication stress tolerance requires novel Aurora kinase antagonists.
Biomarker Validation
Proteomic signatures predict PARP sensitivity but lack prospective validation in SCLC trials (Byers et al., 2012). STING activation biomarkers need refinement for immunotherapy combos (Sen et al., 2019). Integrating SLFN11 expression with clinical outcomes remains challenging.
Essential Papers
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen, B. Leticia Rodriguez, Limo Chen et al. · 2019 · Cancer Discovery · 837 citations
Abstract Despite recent advances in the use of immunotherapy, only a minority of patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that targetin...
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan, Sara M. Tolaney · 2020 · Journal of the National Comprehensive Cancer Network · 618 citations
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negat...
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren A. Byers, Jing Wang, Monique B. Nilsson et al. · 2012 · Cancer Discovery · 555 citations
Abstract Small cell lung cancer (SCLC) is an aggressive malignancy distinct from non–small cell lung cancer (NSCLC) in its metastatic potential and treatment response. Using an integrative proteomi...
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · 2019 · JAMA Oncology · 529 citations
ClinicalTrials.gov identifier: NCT02657889.
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari, Benjamin H. Lok, J. Laird et al. · 2017 · Nature Reviews Clinical Oncology · 474 citations
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang et al. · 2023 · Signal Transduction and Targeted Therapy · 464 citations
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the widespread use ...
Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441
Yan Zhao, Huw D. Thomas, Michael A. Batey et al. · 2006 · Cancer Research · 439 citations
Abstract DNA double-strand breaks (DSB) are the most cytotoxic lesions induced by ionizing radiation and topoisomerase II poisons, such as etoposide and doxorubicin. A major pathway for the repair ...
Reading Guide
Foundational Papers
Start with Byers et al. (2012, 555 citations) for PARP1 proteomic discovery in SCLC; Zhao et al. (2006, 439 citations) for DNA-PK inhibitor mechanisms underpinning DDR targeting.
Recent Advances
Sen et al. (2019, 837 citations) for PARP-STING immunotherapy; Pietanza et al. (2018, 387 citations) for veliparib clinical data; Sabari et al. (2017, 474 citations) for therapy implications.
Core Methods
Proteomic/transcriptomic integration (Byers et al., 2012); phase II randomized trials with PARP-chemo combos (Pietanza et al., 2018); STING pathway assays (Sen et al., 2019).
How PapersFlow Helps You Research Targeted Therapy in Small Cell Lung Cancer
Discover & Search
Research Agent uses searchPapers('PARP inhibitors SCLC SLFN11') to find Byers et al. (2012), then citationGraph reveals 555 citing papers on DDR targets, and findSimilarPapers uncovers Sen et al. (2019) for STING immunity links.
Analyze & Verify
Analysis Agent applies readPaperContent on Pietanza et al. (2018) to extract veliparib trial PFS data, verifyResponse with CoVe checks claims against raw abstracts, and runPythonAnalysis computes survival stats from trial tables using pandas; GRADE scores evidence as high for phase II combos.
Synthesize & Write
Synthesis Agent detects gaps in DLL3 targeting post-Byers et al. (2012), flags contradictions between preclinical PARP data and Pietanza trial results; Writing Agent uses latexEditText for methods sections, latexSyncCitations for 20+ refs, and latexCompile to generate review manuscripts with exportMermaid for DDR pathway diagrams.
Use Cases
"Analyze survival data from veliparib + temozolomide SCLC trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas on Pietanza et al. 2018 hazard ratios) → matplotlib survival plots output.
"Write LaTeX review on PARP targeting in SLFN11-high SCLC"
Synthesis Agent → gap detection on Byers/Sen papers → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF with citations.
"Find code for SCLC proteomic analysis pipelines"
Research Agent → paperExtractUrls (Byers 2012) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R/Python scripts for pathway analysis.
Automated Workflows
Deep Research workflow scans 50+ SCLC papers via searchPapers, structures PARP inhibitor evidence into GRADE-graded reports with citationGraph clusters. DeepScan's 7-step chain verifies Sen et al. (2019) STING claims using CoVe on 20 similar papers. Theorizer generates hypotheses on Aurora-SLFN11 synthetic lethality from Byers proteomic data.
Frequently Asked Questions
What defines targeted therapy in SCLC?
Targeted therapy in SCLC focuses on PARP inhibitors for SLFN11-high tumors and Aurora antagonists for replication stress, distinct from NSCLC drivers.
What are key methods in SCLC targeted therapy?
Proteomic profiling identifies PARP1 targets (Byers et al., 2012); clinical trials test PARP inhibitor combos like veliparib-temozolomide (Pietanza et al., 2018).
What are key papers on PARP in SCLC?
Byers et al. (2012, 555 citations) profiles PARP1 vulnerabilities; Sen et al. (2019, 837 citations) links PARP targeting to STING immunity; Pietanza et al. (2018) reports phase II veliparib results.
What open problems exist?
Validating SLFN11 biomarkers prospectively, overcoming relapse resistance, and expanding beyond PARP to DLL3/Aurora targets lack large trials.
Research Lung Cancer Research Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Targeted Therapy in Small Cell Lung Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lung Cancer Research Studies Research Guide